Short answer
OPKO HEALTH, INC. (OPK) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$54M
- −347.5% YoY · −536.1% QoQ
- EPS (diluted)
- −$0.08
- −260.0% YoY · −700.0% QoQ
Source: XBRL data from the OPKO HEALTH, INC. (OPK) Q3 2026 10-Q on SEC EDGAR. USD.
OPKO HEALTH, INC. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $65.4M, up 16% YoY from $56.4M, driven by Eli Lilly royalties and Rayaldee sales
- Operating loss $31.4M vs $33.6M YoY, equivalent margins of -48.0% vs -59.5%
- Best segment Global Products: revenue $48.4M, operating income $6.0M vs loss $1.2M
- Worst segment Innovative Biotech: operating loss $26.8M vs $22.5M, R&D $30.4M vs $26.3M
- Cash, equivalents and restricted cash $403.2M; operating cash use $99.1M and royalty-note proceeds $123.1M YTD
- Outlook: liquidity expected sufficient beyond 12 months, with risks from pipeline spending, clinical milestones, financing needs and tariffs
Risk Factors
- No material changes to risk factors from the most recent Form 10-K
- Key carried-forward risks remain those disclosed in the Form 10-K, without quarterly updates
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other OPKO HEALTH, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.